

In response to the April 11, 2000 Office Action in U.S. Patent Application No. 09/430,735, please amend the application as follows:

In the title:

Replace "Blood-Brain Barrier Therapeutics" with --Method for Inducing Analgesia--.

In the claims:

Cancel claims 23-25, 51-60, 66-67, and 72.

In claim 51, replace "41" with --46-- *Self (1E)*

Amend claims 46-50 as follows:

Sub H2 C1
46. A method for inducing analgesia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an amphiphilic drug-oligomer conjugate comprising [enkephalin] an opioid conjugated to an oligomer, wherein the oligomer comprises [a] one or more lipophilic [moiety] moieties coupled to [a] one or more hydrophilic [moiety] moieties.

Sub H2 C1
47. The method of claim [41] 46 wherein the [therapeutic compound] opioid is [met⁵]enkephalin.

Sub H2 C2
48. The method of claim [41] 46 wherein the one or more lipophilic moiety is selected from the group consisting of fatty acids, C₁₋₂₆ alkyls, and cholesterol.

49. The method of claim [41] 46 wherein the one or more hydrophilic moieties are selected from the group consisting of sugars and PEG.

50. The method of claim [41] 46 wherein the one or more hydrophilic [moiety comprises] moieties comprise a sugar [and the sugar is] selected from the group consisting of amino sugars and non-amino sugars.

C3 Sub H2
70. The method of claim 46 wherein the [therapeutic compound is an] opioid is an enkephalin.

71. The method of claim 46 wherein the [therapeutic compound is an enkephalin] opioid is a non-naturally occurring opioid.

Add the following new claims:

73. The method of claim 46 wherein the subject is a human.
74. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered orally.
75. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered intravenously.
76. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered by a route selected from the group consisting of pulmonary, intraosseal, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal and epidural.
77. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered by a route selected from the group consisting of intraventricular and intrathecal.
78. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition.
79. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for oral administration.
80. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for intravenous administration.
81. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for administration by a route selected from the group consisting of pulmonary, intraosseal, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal and epidural.

82. The method of claim 46 wherein the amphiphilic drug-oligomer conjugate is administered as a component of a pharmaceutical composition formulated for administration by a route selected from the group consisting of intraventricular and intrathecal.

83. A method for inducing analgesia comprising administering to a subject in need thereof an analgesia-inducing amount of a cetyl-PEG₂-enkephalin conjugate.

84. A method for inducing analgesia comprising administering to a subject in need thereof an analgesia-inducing amount of a DHA-PEG₂-enkephalin conjugate.

85. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



wherein n=3 to 25 and m=1 to 6.

86. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



wherein n=3 to 25 and m=1 to 7.

87. The method of claim 46 wherein the oligomer ~~is~~ has a formula:




wherein n=3 to 25, m=1 to 7 and X=O or N.

88. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



wherein m=0 to 5 and R=cholesterol or adamantane.


89. The method of claim 46 wherein the oligomer ~~is~~ has a formula:



(Formula 5),

wherein $m=0$ to 4 and R =cholesterol or adamantane.


90. The method of claim 46 wherein the oligomer is has a formula:



(Formula 6),

wherein $m=0$ to 7.


Sub D1
91. The method of claim 46 wherein the oligomer is has a formula:




(Formula 7),

wherein $m=1$ to 7 and $X=N$ or O .


92. The method of claim 46 wherein the drug-oligomer conjugate has a formula:



Sub 92
93. The method of claim 46 wherein the drug-oligomer conjugate has a formula:



94. The method of claim 46 wherein the drug-oligomer conjugate has a formula:



- [illegible]

- [illegible]

- $$\begin{array}{c} \text{H}_3\text{C}-(\text{H}_2\text{C})_{14}-\overset{\text{O}}{\parallel}\text{C}-(\text{OC}_2\text{H}_4)_3\text{O}-\overset{\text{O}}{\parallel}\text{C}- \\ | \\ \text{HN-Tyr-Gly-Gly-Phe-Met-Lys}-\overset{\text{O}}{\parallel}\text{C}-\text{OH} \\ | \\ \text{N}-\overset{\text{O}}{\parallel}\text{C}-\text{O}(\text{C}_2\text{H}_4\text{O})_3-\overset{\text{O}}{\parallel}\text{C}-(\text{CH}_2)_{14}-\text{CH}_3 \\ | \\ \text{H} \end{array}$$